Phase 1Completed

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
29 enrolled
Conditions
Hepatitis C Virus
Interventions
tacrolimus; TMC435; cyclosporine; TMC435
Ages
adults
Registry
NCT01479881, EUCTR2011-003021-96

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 (administered once a day) on the single-dose pharmacokinetics of the immunosuppressants cyclosporine and tacrolimus in healthy participants. Cyclosporine and tacrolimus are immunosuppressants used to prevent transplant rejection and may therefore potentially be coadministered with TMC435 in patients infected with hepatitis C virus that undergo liver transplantation. We will also explore the short-term safety and tolerability following coadministration of TMC435 at steady-state and (1) cyclosporine or (2) tacrolimus after single dosing in healthy participants. Steady-state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.

Primary outcomes

  • Change in the steady-state plasma concentration (PK) of cyclosporine and tacrolimus following co-administration with TMC435.

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started